Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378313 · ClinicalTrials.gov registry record · Phase 2
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
A Phase 2 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT00378313 is a Phase 2 study that has completed, run by NSABP Foundation. The registered enrollment target is 76 participants.
The verdict
NCT00378313, a Phase 2 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given before surgery to patients with locally advanced breast cancer. This study will also evaluate the toxicity of the chemotherapy combination to patients and will determine survival and progression-free survival 2 years after treatment. Also, the study will look at whether there are molecular and genetic changes in the tumor tissue that match the tumor's response to the chemotherapy.
Interventions
- DRUG gemcitabine, epirubicin, paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378313
The ClinicalTrials.gov registry entry for NCT00378313 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gemcitabine, epirubicin, paclitaxel is the first listed.
NCT00378313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00378313 about?
NCT00378313 is a clinical study titled "A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer". The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given before surgery to patients with locally advanced breast cancer. This stud...
What is the current status of trial NCT00378313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2001-11. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00378313?
The interventions under investigation include: gemcitabine, epirubicin, paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00378313?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.